



1625 / ED

PTO/SB/21 (09-04)

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/532,271
Filing Date	November 8, 2005
First Named Inventor	Jones, Peter
Art Unit	
Examiner Name	
Attorney Docket Number	020891-001520US
Total Number of Pages in This Submission	12

## ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard References Cited (107) Copy of International Search Report
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Townsend and Townsend and Crew LLP		
Signature			
Printed name	William B. Kezer		
Date	March 22, 2006	Reg. No.	37,369

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature			
Typed or printed name	Marta R. Vanegas	Date	March 22, 2006

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On

Mardi 22, 2006

TOWNSEND and TOWNSEND and CREW LLP

By:

Marta Vanegas



PATENT  
Attorney Docket No.: 020891-001520US  
Client Ref. No.: GSFT015-PCT/US-2

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Jones, Peter et al.

Application No.: 10/532,271

Filed: November 8, 2005

For: ANTI-INFECTIVE BIARYL  
COMPOUNDS

Examiner:

Art Unit:

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the foreign patent and of the non-patent references [in compliance with the requirements of 37 CFR §1.98(a)(2)] are enclosed herewith.

Also enclosed is a copy of the International Search Report for the corresponding International Application No. PCT/US03/33617.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



William B. Kezer  
Reg. No. 37,369

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 925-472-5000  
Fax: 925-472-8895  
WBK:mrw



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

8

**Complete if Known**

Application Number	10/532,271
Filing Date	November 8, 2005
First Named Inventor	Jones, Peter
Art Unit	
Examiner Name	
Attorney Docket Number	020891-001520US

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US- 3,622,574	11-1971	Wright et al.	
	2	US- 4,738,980	04-1988	Arcamone et al.	
	3	US- 4,766,142	08-1988	Arcamone et al.	
	4	US- 4,800,211	01-1989	Tischler et al.	
	5	US- 4,912,199	03-1990	Lown et al.	
	6	US- 5,017,599	05-1991	Lazzari et al.	
	7	US- 5,049,579	09-1991	Lazzari et al.	
	8	US- 5,310,752	05-1994	Lazzari et al.	
	9	US- 5,350,748	09-1994	Boschelli et al.	
	10	US- 5,395,849	03-1995	Wittman et al.	
	11	US- 5,472,976	12-1995	Animati et al.	
	12	US- 5,502,068	03-1996	Lown et al.	
	13	US- 5,545,640	08-1996	Beaulieu et al.	
	14	US- 5,616,606	04-1997	Lown et al.	
	15	US- 5,670,534	09-1997	Animati et al.	
	16	US- 5,698,674	12-1997	Bruice et al.	
	17	US- 5,753,629	05-1998	Beria et al.	
	18	US- 5,801,155	09-1998	Kutyavin et al.	
	19	US- 5,808,087	09-1998	Matsunaga et al.	
	20	US- 5,821,258	10-1998	Matsunaga.	
	21	US- 5,844,110	12-1998	Gold	
	22	US- 5,852,011	12-1998	Matsunaga et al.	
	23	US- 5,998,140	12-1999	Dervan et al.	
	24	US- 6,090,947	07-2000	Dervan et al.	
	25	US- 6,143,901	11-2000	Dervan	
	26	US- 6,153,642	11-2000	Cozzi et al.	
	27	US- 6,172,104	01-2001	Tidwell et al.	
	28	US- 6,458,768	10-2002	Cozzi et al.	
	29	US- 6,555,693	04-29-2003	Ge et al.	
	30	US- 6,566,393 B1	05-20-2003	Lee et al.	
	31	US- 6,586,561 B1	07-01-2003	Litt et al.	
	32	US- 2003-0199516-A1	10-23-2003	Moser et al.	
	33	US- 2003-0211508-A1	11-13-2003	Ge et al.	
	34	US- 2003-0236198-A1	12-25-2003	Bürli et al.,	
	35	US- 6,716,866 B2	04-06-2004	McMinn et al.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/532,271
				Filing Date	November 8, 2005
				First Named Inventor	Jones, Peter
				Art Unit	
				Examiner Name	
Sheet	2	of	8	Attorney Docket Number	020891-001520US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	36	US- 6,777,425	08-17-2004	Bürli et al.,	
	37	US- 6,825,228	11-30-2004	Bürli et al.	
	38	US- 2005-0004042-A1	01-06-2005	Hu et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
	39	DE	199 20 936	A1	11-09-2000	BASF A.G.		
	40	GB	2 310 207	A	02-15-1996	Pharmacia & Upjohn S.p.A.		
	41	JP	08-027146	A	10-15-1996	Mitsui Toatsu Chem. Inc.		
	42	JP	08-269008	A	10-15-1996	Mitsui Toatsu Chem. Inc.		
	43	JP	11-171886	A	06-29-1999	Mitsui Chem. Inc.		
	44	JP	11-189594	A	07-13-1999	Mitsui Chem. Inc.		
	45	WO	92/13838	A1	08-20-1992	Synphar Laboratories, Inc.		
	46	WO	93/13739	A2	07-22-1993	Menarini Industrie Farmaceutiche Reunite S.R.L.		
	47	WO	94/20463	A1	09-15-1994	Menarini Industrie Farmaceutiche Reunite S.R.L.		
	48	WO	95/24419	A1	09-14-1995	Ariad Pharmaceuticals, Inc.		
	49	WO	96/26950	A1	09-06-1996	Pharmacia S.P.A.		
	50	WO	97/03957	A1	02-06-1997	Pharmacia & Upjohn S.P.A.		
	51	WO	97/25351	A2	07-17-1997	Leukosite, Inc.		
	52	WO	97/28123	A1	08-07-1997	Pharmacia & Upjohn S.P.A.		
	53	WO	98/21202	A1	05-22-1998	Pharmacia & Upjohn S.P.A.		
	54	WO	98/35702	A1	08-20-1998	California Institute of Technology		
	55	WO	98/37066	A1	08-27-1998	California Institute of Technology		
	56	WO	98/37067	A1	08-27-1998	California Institute of Technology		
	57	WO	98/37087	A1	08-27-1998	California Institute of Technology		
	58	WO	98/43663	A1	10-08-1998	The Scripps Research Institute		
	59	WO	98/45284	A1	10-15-1998	California Institute of Technology		
	60	WO	98/49142	A1	11-5-1998	California Institute of Technology		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/532,271
				Filing Date	November 8, 2005
				First Named Inventor	Jones, Peter
				Art Unit	
				Examiner Name	
Sheet	3	of	8	Attorney Docket Number	020891-001520US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
	61	WO	98/50582	A1	11-12-1998	California Institute of Technology		
	62	WO	98/52614	A2	11-26-1998	The Board of Trustees of the Leland Stanford Junior University		
	63	WO	99/00364	A1	01-07-1999	Pharmacia & Upjohn S.P.A.		
	64	WO	99/25686	A1	05-27-1999	Teijin Limited		
	65	WO	99/27939	A1	06-10-1999	The Government of the U.S.A.		
	66	WO	99/41367	A1	08-19-1999	Merck Patent GmbH		
	67	WO	99/50265	A1	10-07-1999	Pharmacia & Upjohn S.P.A.		
	68	WO	99/50266	A1	10-07-1999	Pharmacia & Upjohn S.P.A.		
	69	WO	99/62890	A1	12-09-1999	Pfizer Products Inc.		
	70	WO	99/64413	A1	12-16-1999	Pharmacia & Upjohn S.P.A.		
	71	WO	00/06541	A1	02-10-2000	Pharmacia & Upjohn S.P.A.		
	72	WO	00/06542	A1	02-10-2000	Pharmacia & Upjohn S.P.A.		
	73	WO	00/15209	A2	03-23-2000	The Scripps Research Inst.		
	74	WO	00/15773	A2	03-23-2000	California Institute of Technology		
	75	WO	00/40605	A2	07-13-2000	Genesoft, Inc.		
	76	WO	00/69432	A1	11-23-2000	Teijin Limited		
	77	WO	01/10439	A1	02-15-2001	Teijin Limited		
	78	WO	01/19792	A1	03-22-2001	Genelabs Technologies, Inc.		
	79	WO	01/21615	A1	03-29-2001	Yamanouchi Pharmaceutical Co., Ltd.		
	80	WO	01/74898	A2	10-11-2001	Genesoft, Inc.		
	81	WO	01/96313	A1	12-20-2001	The Scripps Research Institute		
	82	WO	02/00650	A2	01-03-2002	Genelabs Technologies, Inc.		
	83	WO	02/088119	A1	11-07-2002	Genesoft, Inc.		
	84	WO	02/101073	A2	12-19-2002	Genesoft, Inc.		
	85	WO	04/012736	A1	02-12-2004	Genesoft Pharmaceuticals, Inc.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/532,271
				Filing Date	November 8, 2005
				First Named Inventor	Jones, Peter
				Art Unit	
				Examiner Name	
Sheet	4	of	8	Attorney Docket Number	020891-001520US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	86	ARCAMONE, F. et al., "Synthesis, DNA binding and antiviral activity of distamycin analogues containing different heterocyclic moieties." <i>Anti-Cancer Drug Design</i> , 1:235-244 (1986).		
	87	BAILLY, C. and J.B. Chaires, "Sequence-specific DNA minor groove binders. Design and synthesis of netropsin and distamycin analogues." <i>Bioconj. Chem.</i> , 9(5):513-538 (1998).		
	88	BAIRD, E.E. and P.B. Dervan, "Solid phase synthesis of polyamides containing imidazole and pyrrole amino acids." <i>J. Am. Chem. Soc.</i> , 118:6141-46 (1996).		
	89	BARALDI et al., "Synthesis of 3-Substituted-7-alkoxy-5H-pyrazolo [4, 3-d],2,3-triazin-4(3H)-ones" <i>Synthesis</i> , pp. 1437-1440, (1994), XP002208604.		
	90	BARALDI, P.G. et al., "Synthesis and antitumor activity of new benzoheterocyclic derivatives of distamycin A." <i>J. Med. Chem.</i> , 43:2675-2684 (2000).		
	91	BERGE, S.M., et al, "Pharmaceutical Salts", <i>J. Pharm. Sci.</i> , 66:1-19 (1977)		
	92	BILDER G. et al., "Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A." <i>Circulation</i> , 99(25):3292-99 (1999)		
	93	BOGER, D.L. et al., "A simple, high-resolution method for establishing DNA binding affinity and sequence selectivity." <i>J. Am. Chem. Soc.</i> , 123:5878-91 (2001)		
	94	BOGER, D.L. et al., "Total synthesis of distamycin A and 2640 analogues: A solution-phase combinatorial approach to the discovery of new bioactive DNA binding agents and development of a rapid high-throughput screen for determining relative DNA binding affinity or DNA binding sequence selectivity." <i>J. Am. Chem. Soc.</i> , 122:6382-94 (2000).		
	95	BREMER, R.E. et al., "Recognition of the DNA minor groove by pyrrole-imidazole polyamides: comparison of desmethyl- and n-methylpyrrole." <i>Bioorg. Med. Chem.</i> , 8:1947-55 (2000).		
	96	BRUCE, Thomas C. et al., "Rational design of substituted tripyrrole peptides that complex with DNA by both selective minor-groove binding and electrostatic interaction with the phosphate backbone." <i>Proc. Natl. Acad. Sci. USA</i> , 89:1700-04 (1992)		
	97	CHIARINO, D. et al., "Synthesis of new isoxazole aminoalcohols." <i>J. Heterocyclic Chem.</i> , 25(1):337-342 (1988)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/532,271
				Filing Date	November 8, 2005
				First Named Inventor	Jones, Peter
				Art Unit	
				Examiner Name	
Sheet	5	of	8	Attorney Docket Number	020891-001520US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	98	CHOUDHURY, G.G. et al., "Involvement of PKC-alpha in PDGF-mediated mitogenic signaling in human mesangial cells." <i>Am. J. Physiol.</i> , 265(5 Pt 2):F634-42 (1993)		
	99	CORALLINI, A. et al. "Characterization of the effects of two polysulfonated distamycin A derivatives, PNU145156E and PNU153429, on HIV type 1 Tat protein." <i>AIDS Res. Hum. Retroviruses</i> , 4(17):1561-71 (1998)		
	100	DYATKINA, N.B. et al., "Minor groove DNA binders as antimicrobial agents. 1. Pyrrole tetraamides are potent antibacterials against vancomycin resistant Enterococci [corrected] and methicillin resistant Staphylococcus aureus." <i>J. Med. Chem.</i> ; 45(4):805-17 (2002)		
	101	ELLERVIK, U. et al., "Hydroxybenzamide/pyrrole pair distinguishes T-A from A-T base pairs in the minor groove of DNA" <i>J. Am. Chem. Soc.</i> 122(39):9354-60 (2000)		
	102	EL-NAGGAR, A.M. et al., "Synthesis of some 2-thenoyl-, 5-bromo-2-thenoyl- and 5-nitro-2-thenoylamino acid derivatives and their antimicrobial activity." <i>J. Indian Chem. Soc.</i> , LIX:783-786 (1982).		
	103	FENWICK et al., "Solid-phase synthesis of cyclic alkoxyketones, inhibitors of the cysteine protease cathepsin K." <i>Bioorg. Med. Chem. Lett.</i> , 11:195-98 (2001).		
	104	FLOREANCIG, P.E. et al., "Recognition of the minor groove of DNA by hairpin polyamides containing alpha-substituted-beta-amino acids." <i>J. Am. Chem. Soc.</i> , 122:6342-50 (2000).		
	105	GOODSELL D. and R.E. Dickerson, "Isohelical analysis of DNA groove-binding drugs." <i>J. Med. Chem.</i> , 29(5):727-33 (1986)		
	106	GOUGEROT-POCIDALO, M.A. et al. "Mechanisms by which oxidative injury inhibits the proliferative response of human lymphocytes to PHA. Effect of the thiol compound 2-mercaptoethanol." <i>Immunology</i> , 64(2):281-8 (1988)		
	107	GUPTA et al., "Hybrid molecules containing propargylic sulfones and DNA minor groove-binding lexitropsins: synthesis, sequence specificity of reaction with DNA and biological evaluation." <i>Gene</i> , 149:81-90 (1994)		
	108	HANDLER, J.A. et al., "Mitogenic signaling by epidermal growth factor (EGF), but not platelet-derived growth factor, requires arachidonic acid metabolism in BALB/c 3T3 cells. Modulation of EGF-dependent c-myc expression by prostaglandins." <i>J. Biol. Chem.</i> , 265(7):3669-73 (1990)		
	109	HELDIN C.H. and B. Westermarck, "Mechanism of action and in vivo role of platelet-derived growth factor." <i>Physiol. Rev.</i> ; 79(4):1283-316 (1999)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/532,271
				Filing Date	November 8, 2005
				First Named Inventor	Jones, Peter
				Art Unit	
				Examiner Name	
Sheet	6	of	8	Attorney Docket Number	020891-001520US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	110	HERMAN, D.M. et al., "Cycle Polyamide Motif for Recognition of the Minor Groove of DNA." <i>J. Am. Chem. Soc.</i> , 121(6):1121-29 (1999)		
	111	KELLY, J.J. et al., "Binding site size limit of the 2:1 pyrrole-imidazole polyamide-DNA motif." <i>Proc. Natl. Acad. Sci. USA</i> , 93:6981-85 (1996)		
	112	KHALAF, A.I. et al., "The synthesis of some head to head linked DNA minor groove binders." <i>Tetrahedron</i> , 56:5225-39 (2000)		
	113	KOPKA, M.L. et al., "Defining GC-specificity in the minor groove: side-by-side binding of the di-imidazole lexitropsin to C-A-T-G-G-C-A-T-G." <i>Structure</i> , 5(8):1033-46 (1997).		
	114	MACHON, Z. and S. Ryng, "Synthesis and biological properties of 5-benzoylamino-3-methyl-4-isoxazolocarboxylic acid derivatives." <i>Arch. Immunol. Ther. Exp. (Warsz)</i> , 29(6):813-21 (1981)		
	115	MATSUBA, Y. et al., "A novel synthetic DNA minor groove binder, MS-247: antitumor activity and cytotoxic mechanism." <i>Cancer Chemo. Pharm.</i> , 46:1-9 (2000)		
	116	MATSUMOTO, T. et al., "Synthesis of sulfonamido oligo-N-methylpyrrole-carboxamide derivatives and their photochemical DNA cleaving activities." <i>Heterocycles</i> , 33(1):135-138 (1992)		
	117	MATUSOMOTO, T. et al. "Synthesis of halogenated oligo-N-methylpyrrole-carboxamide derivatives and their photochemical DNA cleaving activities." <i>Heterocycles</i> , 34(9):1697-1702 (1992)		
	118	MRKSICH, M. et al., "Hairpin peptide motif, a new class of oligopeptides for sequence-specific recognition in the minor groove of double-helical DNA." <i>J. Am. Chem. Soc.</i> , 116:7983-88 (1994)		
	119	NEIDLE, S., "DNA minor-groove recognition by small molecules." <i>Nat. Prod. Rep.</i> , 18:291-309 (2001)		
	120	NGUYEN, J.T. et al. "Exploiting the basis of proline recognition by SH3 and WW domains: design of N-substituted inhibitors." <i>Science</i> , 282(5396):2088-92 (1998)		
	121	NIELSEN, P.E. "Sequence-Selective DNA Recognition by Synthetic Ligands." <i>Bioconjug. Chem.</i> , 2(1):1-12 (1991).		
	122	PAE, A.N. et al., "Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles", <i>Bioorg. Med. Chem. Lett.</i> , 9:2679-84 (1999)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/532,271
				Filing Date	November 8, 2005
				First Named Inventor	Jones, Peter
				Art Unit	
				Examiner Name	
Sheet	7	of	8	Attorney Docket Number	020891-001520US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	123	PLESCIA, S. et al., "3 $\alpha$ -hydroxysteroid dehydrogenase inhibitory activity of some N(3)-(1-R-4-carboxypyrazol-5-yl)-1,2,3-benzotriazin-4(3H)-one and quinazoline-4(3H)-one acids." <i>Il Farmaco</i> , 49(7,8):505-07 (1994)		
	124	PLOUVIER, B. et al., "DNA-sequence specific recognition by a thiazole analogue of netropsin: a comparative footprinting study." <i>Nucl. Acids Res.</i> , 19(21):5821-5829 (1991).		
	125	RAO, K.E. et al., "Interaction of synthetic analogues of distamycin and netropsin with nucleic acids. Does curvature of ligand play a role in distamycin-DNA interactions?" <i>Biochemistry</i> , 27(8):3018-24 (1988)		
	126	RAO, K.E. et al., "Molecular recognition between oligopeptides and nucleic acids: DNA sequence specificity and binding properties of thiazole-lexitropsins incorporating the concepts of base site acceptance and avoidance." <i>Anti-Cancer Drug Design</i> , 5:3-20 (1990).		
	127	RENKEMA, G.H. and K. Saksela, "Interactions of HIV-1 NEF with cellular signal transducing proteins." <i>Frontiers in Bioscience</i> , 5:d268-83 (2000)		
	128	SAKAI, Y. et al., "Synthesis of halogenated thiazole derivatives of oligo-N-methylpyrrolicarboxamide and their photochemical DNA cleaving activities." <i>Heterocycles</i> , 36(3):565-73 (1993)		
	129	SEN et al., "Synthesis of Compounds Related to Reserpine Skeleton." <i>J. Indian Chem. Soc.</i> , 46(3):209-15, also in <i>Chemical Abstracts</i> 71(1):318 (1969)		
	130	SHARMA et al., "Design and Synthesis of Novel Thiazole-Containing Cross-Linked Polyamides Related to the Antiviral Antibiotic Distamycin." <i>J. Org. Chem</i> , p. est: 5.3 (1999).		
	131	TANIS, Steven P. and David B. Head, "Furans in synthesis. The preparation of (.+.)-lactaral", <i>Tetrahedron Lett.</i> , 23:(52) pp. 5509-5512 (1982)		
	132	TAYLOR, J.S. et al., "DNA affinity cleaving : Sequence specific cleavage of DNA by Distamycin-EDTA - Fe(II) and EDTA-distamycin Fe(II)." <i>Tetrahedron</i> , 40(3):457-65 (1984)		
	133	TRAUGER, J.W. et al., "Recognition of DNA by designed ligands at subnanomolar concentrations." <i>Nature</i> , 382:559-61 (1996)		
	134	VAQUERO et al., "Small ligands that neither bind to nor alter the structure of d(GA.TC)n sequences in DNA." <i>FEBS Letters</i> , 420:156-60 (1997)		
	135	WADE W.S. et al., "Binding affinities of synthetic peptides, pyridine-2-carboxamidonetropsin and 1-methylimidazole-2-carboxamidonetropsin, that form 2:1 complexes in the minor groove of double-helical DNA." <i>Biochemistry</i> , 32(42):11385-89 (1993)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/532,271
				Filing Date	November 8, 2005
				First Named Inventor	Jones, Peter
				Art Unit	
				Examiner Name	
Sheet	8	of	8	Attorney Docket Number	020891-001520US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	136	WADE, W.S. et al., "Design of peptides that bind in the minor groove of DNA at 5'-(A,T)G(A,T)C(A,T)-3' sequences by a dimeric side-by-side motif." <i>J. Am. Chem. Soc.</i> , 114(23):8783-94 (1992)		
	137	WADE, W.S., "Sequence specific complexation of B DNA at sites containing G,C base pairs." Ph.D. Thesis, California Institute of Technology, Pasadena, CA (1989)		
	138	WHITE, S. et al., "Recognition of the four Watson-Crick base pairs in the DNA minor groove by synthetic ligands." <i>Nature</i> , 391:468-71 (1998)		
	139	WHITE, S. et al., "On the pairing rules for recognition in the minor groove of DNA by pyrrole-imidazole polyamides." <i>Chemistry &amp; Biology</i> , 4:569-578 (1997)		
	140	XIE, G. et al., "Protein kinase C- $\alpha$ inhibitors; structure-activity relationships in bis-indole series." <i>Bioorg. Med. Chem. Lett.</i> , 5(5):497-500 (1995)		
	141	XIE, G. et al., Synthesis and DNA cleaving properties of hybrid molecules containing propargylic sulfones and minor groove binding lexitropsins." <i>Bioorg. Med. Chem. Lett.</i> , 3(8):1565-70 (1993)		
	142	XUE, C.B. et al, "Synthesis and Antiplatelet Effects of An Isoxazole Series of Glycoprotein IIb/IIIa Antagonists", <i>Bioorg. Med. Chem. Lett.</i> , 8:3499-3504 (1998)		
	143	YAMORI, T. et al., "Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel." <i>Cancer Res.</i> , 59(16):4042-49 (1999)		
	144	ZAKRZEWSKA, K. et al., "Drug recognition of DNA. Proposal for GC minor groove specific ligands: vinyllexins." <i>J. Biomol. Struct. Dyn.</i> , 6(2):1043-1058 (1989)		
	145	ZAKRZEWSKA, K. et al., "Theoretical study of the sequence selectivity of isolexins, isohelical DNA groove binding ligands. Proposal for the GC minor groove specific compounds." <i>J. Biomol. Struct. Dyn.</i> , 5(5):1043-1058 (1988)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.